BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on The Company and its subsidiaries (collectively, the “Group”) are principally engaged in clinical stage biopharmaceutical activities focused on the development of innovative cancer therapies. The Company is under the control of Mr. Linqing Jia and Dr. Lan Huang as a couple (collectively, the “Founders”) since its incorporation.

 

On the Company completed its initial public offering (“IPO”) on the NASDAQ Capital Market. ordinary shares were sold at per share (the “IPO Price”). In conjunction with the IPO, ordinary shares were sold in a private placement to certain investors at the same IPO Price. Net proceeds from the IPO and private placement after deducting underwriting discount and offering expenses were The underwriting discount and offering expenses including those recorded as deferred IPO costs were recorded as a reduction of the proceeds received from the IPO in the shareholders’ equity. Immediately prior to the IPO, the Company issued ordinary shares to NPBSIPO Liquidating Trust, or Nereus Trust in connection with termination of royalty payment arrangement (Note ).

 

As at the subsidiaries of the Company are as follows:

 

 

The accompanying unaudited interim condensed consolidated balance sheet as of the unaudited interim condensed consolidated statements of comprehensive loss and cash flows for the months ended and and the related footnote disclosures are unaudited. These unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP for interim financial information using accounting policies that are consistent with those used in the preparation of the Company’s audited consolidated financial statements for the year ended Accordingly, these unaudited interim condensed consolidated financial statements do include all of the information and footnotes required by U.S. GAAP for annual financial statements.

In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Group for each of the periods presented. The results of operations for the months ended are necessarily indicative of results to be expected for any other interim period or for the full year of The consolidated balance sheet as of was derived from the audited consolidated financial statements at that date but does include all of the disclosures required by U.S. GAAP for annual financial statements. These unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended